Adjuvant Tamoxifen Influences the Lipid Profile in Breast Cancer Patients

Abstract

Background: Currently there is a debate regarding whether tamoxifen used in breast cancer has an impact on lipid profiles. The aim of this study was to determine whether tamoxifen has an impact on the serum lipid profile in Taiwanese women. Patients and Methods: Data of 109 patients were collected from the routine clinical follow-up for women with hormone receptor-positive breast cancer who were treated between July 2005 and March 2008. These patients were divided into 2 subgroups, based on their tumor grade and lymph node status. Subgroup 1 patients had tumor grade I/II and a negative lymph node status. Those patients with tumor grade III or a positive lymph node status were defined as subgroup 2. Results: In the 109 patients, the mean serum total cholesterol (TC) levels after tamoxifen treatment, as well as the serum low-density lipoprotein cholesterol (LDL-C) levels, were lower than the baseline levels, with statistically significant differences. Treatment with tamoxifen lowered the serum TC and LDL-C levels in both subgroups. Conclusions: The results indicate that tamoxifen has an impact on the serum lipid profile of breast cancer patients in Taiwan. Physicians should follow up the lipid profile in these patients.

Effect of Tamoxifen on Lipid Profile in Iraqi Breast Cancer Women

“…This cross-sectional study show the effect of tamoxifin as a hormonal therapy on lipid profile in women with breast cancer, the results demonstrate a favourable effect of tamoxifen supported by statistically significant decreases in serum TG, TC and LDL-C after tamoxifen treatment in breast cancer patients. The results demonstrated that the serum TC levels were reduced by tamoxifen, in agreement with the results of comparable studies [ 1,10,11].…”

“…Tamoxifen-citrate, a non-steroidal antiestrogen, is one of the most widely used hormonal treatments for patients with breast cancer. Recent studies in pre-and postmenopausal women have shown that tamoxifen exhibits favorable effects on the lipid and lipoprotein profile by decreasing the total and Low Density Lipoprotein (LDL) cholesterol levels as well as the Lipoprotein a (Lp(a)) levels [1][2][3][4]. It has been suggested that its estrogenic activity is mainly responsible for the observed changes in lipid parameters [5,6].…”

Does Adriamycine, Cytoxan with Taxol Treatment Affect FBS and Lipid Profile in Breast Cancer Patients

“…Studies on tamoxifen revealed various contradictory results regarding lipid profile items in breast cancer patients [3,23]. One study on 109 breast cancer patients treated by tamoxifen declared lower LDL and TC level.…”

Associação temporal da terapia endócrina com tamoxifeno e da quimioterapia sobre o risco nutricional e obesidade em pacientes com câncer de mama

“…Muitos estudos sugerem que o TMX adjuvante exibe diferentes alterações no perfil lipídico e hepático de indivíduos com CM (LIN et al, 2014;HERNANDEZ et al, 2008;LEWIS, 2007).…”

“…Em sobreviventes do CM, a terapia endócrina com TMX é utilizada para diminuir a recorrência e mortalidade em mulheres com receptores hormonais positivos (THERIAULT et al, 2013). Entretanto, destaca-se na literatura a ocorrência de efeitos secundários ao tratamento, como a ocorrência de alterações lipídicas (LIN et al, 2014) e modificações na composição corporal, como aumento do peso e gordura corporal (AZRAD; LORIZIO et al, 2012). Entretanto, estas modificações ainda são controversas e precisam ser melhor investigadas durante o tratamento hormonal com o TMX VAN DE VELDE et al, 2010;SESTAK et al, 2010) Além disso, outros tratamentos, como a QT adjuvante, também podem impactar no estado nutricional de pacientes com CM (BOLTONG et al, 2014), sendo considerado um fator prognóstico independente para modificações corporais, com um potencial efeito a longo prazo (TREDAN et al, 2010;GOODWIN et al, 1999).…”